SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Slemenda C, Hui SL, Longcope C, Johnston CC 1987 Sex steroids and bone mass. A study of changes about the time of menopause. J Clin Invest 80: 12611269.
  • 2
    Barrett-Connor E, Mueller JE, von Muhlen DG, Laughlin GA, Schneider DL, Sartoris DJ 2000 Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo Study. J Clin Endocrinol Metab 85: 219223.
  • 3
    Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hamalainen E 1994 Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 86: 10761082.
  • 4
    Lippert TH, Seeger H, Mueck AO 2000 The impact of endogenous estradiol metabolites on carcinogenesis. Steroids 65: 357369.
  • 5
    Leelawattana R, Ziambaras K, Roodman-Weiss J, Lyss C, Wagner D, Klug T, Armamento-Villareal R, Civitelli R 2000 The oxidative metabolism of estradiol conditions postmenopausal bone density and bone loss. J Bone Miner Res 15: 25132520.
  • 6
    Bradlow HL, Telang NT, Sepkovic DW, Osborne MP 1996 2-hydroxyestrone: The ‘good’ estrogen. J Endocrinol 150 (Suppl): S259S265.
  • 7
    Westerlind KC, Gibson KJ, Malone P, Evans GL, Turner RT 1998 Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats. J Bone Miner Res 13: 10231031.
  • 8
    Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berino F 2000 Estrogen metabolism and risk of breast cancer: A prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11: 635640.
  • 9
    Osborne MP, Bradlow HL, Wong GY, Telang NT 1993 Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: A potential biomarker of breast cancer risk. J Natl Cancer Inst 85: 19171920.
  • 10
    Lim SK, Won YJ, Lee JH, Kwon SH, Lee EJ, Kim KR, Lee HC, Huh KB, Chung BC 1997 Altered hydroxylation of estrogen in patients with postmenopausal osteopenia. J Clin Endocrinol Metab 82: 10011006.
  • 11
    Martucci CP, Fishman J 1993 P450 enzymes of estrogen metabolism. Pharmacol Ther 57: 237257.
  • 12
    Badawi AF, Cavalieri EL, Rogan EG 2001 Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 50: 10011003.
  • 13
    Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ 1995 A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 55: 37573758.
  • 14
    Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J 1997 Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 18: 23072311.
  • 15
    Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, Gotoh O, Kawajiri K 2000 Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10: 2533.
  • 16
    Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, Guo C, Le Marchand L 2001 Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 10: 209216.
  • 17
    Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, Lacroix A, Labuda D, Sinnett D 2001 Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer 92: 220225.
  • 18
    Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J 2003 Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer 106: 375378.
  • 19
    Aktas D, Guney I, Alikasifoglu M, Yuce K, Tuncbilek E, Ayhan A 2002 CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 86: 124128.
  • 20
    Michnovicz JJ, Adlercreutz H, Bradlow HL 1997 Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst 89: 718723.
  • 21
    Armamento-Villareal R, Villareal DT, Avioli LV, Civitelli R 1992 Estrogen status and heredity are major determinants of premenopausal bone mass. J Clin Invest 90: 24642471.
  • 22
    Klug TL, Bradlow HL, Sepkovic DW 1994 Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16 alpha-hydroxyestrone in urine. Steroids 59: 648655.
  • 23
    Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD 2001 Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86: 31623165.
  • 24
    Cascorbi I, Brockmoller J, Roots I 1996 A C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 56: 49654969.
  • 25
    Huber JC, Schneeberger C, Tempfer CB 2002 Genetic modeling of estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas 41 (Suppl 1): S55S64.
  • 26
    Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF 2000 Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60: 34403444.
  • 27
    Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K 1999 Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20: 16071613.
  • 28
    Hong CC, Tang BK, Hammond GL, Tritchler D, Yaffe M, Boyd NF 2004 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: A cross-sectional study. Breast Cancer Res 6: R352R365.
  • 29
    Lotinun S, Westerlind KC, Turner RT, Turner RT 2001 Tissue-selective effects of continuous release of 2-hydroxyestrone and 16alpha-hydroxyestrone on bone, uterus and mammary gland in ovariectomized growing rats. J Endocrinol 170: 165174.
  • 30
    Sibonga JD, Lotinun S, Evans GL, Pribluda VS, Green SJ, Turner RT 2003 Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 144: 785792.
  • 31
    Liu G, Peacock M, Eilam O, Dorulla G, Braunstein E, Johnston CC 1997 Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int 7: 564569.
  • 32
    Somner J, McLellan S, Cheung J, Mak YT, Frost ML, Knapp KM, Wierzbicki AS, Wheeler M, Fogelman I, Ralston SH, Hampson G 2004 Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: Association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 89: 344351.
  • 33
    Koller DL, Econs MJ, Morin PA, Christian JC, Hui SL, Parry P, Curran ME, Rodriguez LA, Conneally PM, Joslyn G, Peacock M, Johnston CC, Foroud T 2000 Genome screen for QTLs contributing to normal variation in bone mineral density and osteoporosis. J Clin Endocrinol Metab 85: 31163120.
  • 34
    Michnovicz JJ, Bradlow HL 1990 Dietary and pharmacological control of estradiol metabolism in humans. Ann NY Acad Sci 595: 291299.
  • 35
    Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC Jr 1991 Genetic determinants of bone mass in adult women: A reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J Bone Miner Res 6: 561567.
  • 36
    MacInnis RJ, Cassar C, Nowson CA, Paton LM, Flicker L, Hopper JL, Larkins RG, Wark JD 2003 Determinants of bone density in 30- to 65-year-old women: A co-twin study. J Bone Miner Res 18: 16501656.